Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial

Fig. 4

Changes in MSC-derived immunosuppressive cytokines after MSC infusion. A–H The levels of the MSC-derived immunosuppressive cytokines HO1, GAL1, GAL9, TNFIA6, PGE2, PDL1, TGF-β and HGF were assessed before and 1 day and 7 days after MSC infusion. Compared to the levels before MSC infusion, HO1 (A) and TGF-β (G) increased significantly 1 day after MSC infusion. At 7 days after MSC infusion, there was a trend towards increased levels of HO1 (A), GAL1 (B), TNFIA6 (D) and TGF-β (G), although the differences were not statistically significant

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us